Loxapine in patient with clozapine-resistant psychosis

Jennifer Erley,Sarah Goldsborough,Amy VandenBerg,Alexandra Audu
DOI: https://doi.org/10.9740/mhc.2021.07.263
2021-07-01
Mental Health Clinician
Abstract:Abstract Clozapine is recognized as the drug of choice for treatment-refractory schizophrenia, but use may be limited because of strict monitoring requirements and adverse effects including severe neutropenia, seizures, and myocarditis. Loxapine is a first-generation antipsychotic with similarities to clozapine in both structure and receptor binding. This case describes a 57-year-old male with a history of severe paranoid schizophrenia despite treatment with clozapine and other psychotropic agents, who experienced clinical improvement after a cross titration from clozapine to loxapine. Loxapine may be a reasonable alternative in patients with treatment-refractory schizophrenia who do not tolerate or respond to clozapine.
What problem does this paper attempt to address?